CTNNB1 and hepatocellular carcinoma: In this study, we systematically screened HCC patients for all non-synonymous mutations and with mutation frequencies greater than 10% and found only CTNNB1-MUT to be a suitable independent prognostic factor for those receiving ICI treatment (based on a multivariate COX risk proportional regression model).